COLLOIDAL SOLUTION FOR EX-VIVO LUNG PERFUSION AND STORAGE

Abstract

The present invention relates to a colloidal solution free of human or animal blood derivatives for the ex-vivo perfusion, regeneration and storage of the lungs before transplantation.

Claims

1. A sterile aqueous colloidal solution comprising: hydroxyethyl starch at a concentration within the range of 45-55 g/L; dextran at a concentration within the range of 4-6 g/L; sodium metabisulfite and EDTA sodium salt; and one or more osmotic agents, a buffer system and electrolytes, for use in the medical field for ex-vivo perfusion and storage of isolated lungs to be transplanted.

2. The sterile aqueous colloidal solution according to claim 1, wherein hydroxyethyl starch is present at a concentration of 50 g/L.

3. The sterile aqueous colloidal solution according to claim 1, wherein dextran is present at a concentration of 5 g/L.

4. The sterile aqueous colloidal solution according to claim 1, wherein said one or more osmotic agents are selected from the group consisting of sodium chloride, calcium chloride dihydrate, glucose monohydrate and combinations thereof.

5. The sterile aqueous colloidal solution according to claim 1, wherein said buffer system comprises sodium bicarbonate and sodium phosphate monobasic dehydrate to keep the pH between 7.0-7.5.

6. The sterile aqueous colloidal solution according to claim 1, wherein said electrolytes derive from one or more chlorinated salts, selected from the group consisting of potassium chloride, magnesium chloride hexahydrate or anhydrous, calcium chloride dihydrate or anhydrous, and sodium chloride.

7. The sterile aqueous colloidal solution according to claim 6, wherein the concentration of said chlorinated salts is within the range of 130.00-160.00 mmoles/l of total chloride.

8. A method of ex-vivo perfusion, regeneration and storage of lungs to be transplanted comprising perfusing the lungs to be transplanted with the sterile aqueous colloidal solution according to claim 1.

9. A process for the preparation of the sterile aqueous colloidal solution according to claim 1, comprising the following steps: a) dissolving of the hydroxyethyl starch, dextran and one or more osmotic agents, a buffer system and electrolytes components of the solution in a volume of water for injectable preparations equal to about 80% of the final volume; b) adding the sodium metabisulfite and EDTA sodium salt; c) adjusting the pH to about neutrality by adding NaOH or HCl; d) bringing to volume by adding water for injectable preparations; e) filtering at 0.2 microns; f) filling bags with the filtered solution from step e) under a laminar flow; g) sterilizing the bags in an autoclave at 115° C.-118° C.

10. The process according to claim 9, wherein the sodium metabisulfite is added in step b) at a concentration within the range of 0.2 g/L-0.4 g/L.

11. The process according to claim 9, wherein the sodium metabisulfite is added in step b) at a concentration of about 0.3 g/L.

Description

[0019] In a preferred embodiment of the invention the hydroxyethyl starch is present at a concentration equal to 50 g/L.

[0020] The dextran present in the aqueous solution is a glucose polymer which forms highly branched molecules and increases the viscosity of the solution forming colloids. It has the function of protecting the endothelium of the small capillaries of the pulmonary alveolus from the formation of clots. In a preferred embodiment of the invention, dextran is present in the solution at a concentration equal to 5 g/L.

[0021] The osmotic agent present in the solution is preferably selected from the group consisting of sodium chloride, calcium chloride dihydrate and glucose monohydrate or a combination thereof. According to a preferred embodiment, the sterile aqueous colloidal solution according to the invention has an osmolarity ranging from 280 to 350 mOsm/kg and a density ranging from 1.00 to 1.05 g/cm.sup.3.

[0022] In a particularly preferred embodiment, the buffer system comprises sodium bicarbonate as pH regulator and sodium phosphate monobasic dihydrate as regulator of the buffer system. The pH of the solution is preferably kept at around neutrality between 7.0-7.5.

[0023] The solution is sterile and non-pyrogenic, i.e. free of endotoxins, viruses, prions, bacteria, antibodies, antigens and derivatives from human or animal blood (i.e. albumin).

[0024] The electrolytic composition of the solution ensures maintenance of the chemical-physical balance of the cells. The electrolytic equilibrium is preferably maintained by the addition to the solution of one or more monohydrate or polyhydrate chlorinated salts, such as for example potassium chloride and magnesium chloride hexahydrate. Even more preferably, the above-mentioned chlorinated salts are present in the solution at a concentration within the ranges described in the following Table 1.

TABLE-US-00001 TABLE 1 COMPONENT g/l Range CAS Nr. Sodium chloride 8 7.2-8.8 g/l 7647-14-5 Potassium chloride 0.34 0.30-0.38 g/l 7447-40-7 Calcium chloride 0.22 0.2-0.3 g/l 10035-04-08 Dihydrate Magnesium chloride 0.24 0.2-0.3 g/l 7791-18-6 Hexahydrate Total chlorides 130-160 mmoles/l

[0025] In a preferred embodiment of the invention, the composition of the colloidal aqueous storage solution is indicated in the following Table 2:

TABLE-US-00002 TABLE 2 COMPONENT g mMoles FUNCTION CAS Nr. Hydroxyethyl 50 / Oncotic agent 9005-27-0 starch (HES) 130/0.42 Dextran 40 5 / Colloidal agent 9004-54-0 Increases the viscosity of the solution. Sodium chloride 8 136.8 Osmotic agent. 7647-14-5 Makes the solution isotonic. Glucose 2.18 11 Osmotic agent 5996-10-1 monohydrate Potassium 0.34 4.6 Osmotic agent 7447-40-7 chloride Maintains the cellular electrolytic equilibrium Calcium chloride 0.22 1.5 Osmotic agent 10035-04-08 dihydrate Increases the osmolarity of the solution Magnesium 0.24 1.2 Osmotic agent 7791-18-6 chloride Maintains the cellular hexahydrate electrolytic equilibrium. Sodium 1.26 15 pH regulator 144-55-8 bicarbonate sodium 0.19 1.2 Buffer system regulator 13472-35-0 phosphate monobasic dihydrate Water for enough to Solvent injectable 1,000 mL preparations

[0026] The ions are present in the solution in such quantity as to guarantee the extra-cellular electrolytic composition.

[0027] The sterile aqueous colloidal solution according to the invention can further comprise a chelating agent for maintaining the stability of the sodium bicarbonate, such as, for example, the sodium salt EDTA.

[0028] The present invention also relates to the use of the sterile aqueous colloidal solution detailed above for the ex-vivo perfusion and storage of isolated lungs to be transplanted.

[0029] By applying the aqueous colloidal storage solution according to the invention to the ex-vivo pulmonary perfusion technique (EVLP), the suitability for organ transplantation has in fact been improved.

[0030] The sterile aqueous colloidal solution according to the invention is preferably packaged in PVC-free medical plastic containers (such as for example medical bags) with double sterile wrapping.

[0031] Finally, the invention contemplates a process for the preparation of the aqueous colloidal storage solution described above, comprising the following steps: [0032] a) dissolution of the components of the aqueous colloidal storage solution described above in a volume of water for injectable preparations equal to approximately 80% of the final volume; [0033] b) addition of sodium metabisulfite and EDTA sodium salt; [0034] c) pH adjustment around neutrality by the addition of NaOH (1N) or HCl (1N); [0035] d) bringing to volume by the addition of water for injectable preparations; [0036] e) filtration at 0.2 microns; [0037] f) filling of the bags under a laminar flow; [0038] g) sterilization of the bags in an autoclave at 115° C.-118° C.

[0039] The addition of sodium metabisulfite in step b) is preferably effected at a concentration ranging from 0.2 to 0.4 g/L, preferably 0.3 g/L.

[0040] According to a preferred embodiment, the sodium metabisulfite is added in combination with medical nitrogen.

[0041] The addition of sodium metabisulfite in the dissolution phase allows the oxidation processes of the organic molecules present in the solution to be reduced. The above-mentioned component, during the subsequent sterilization phase, releases sulfur dioxide which acts as an adjuvant for the reduction of the hot oxidation processes of the organic molecules present in the mixture: mixture:

[0042] The chemical reaction that is generated is the following:

2H.sup.++Na.sub.2S.sub.2O.sub.5.fwdarw.2Na+2SO.sub.2+H.sub.2O

[0043] This is a technological expedient for preserving the chemical-physical characteristics of the molecules in solution during the sterilization phase.

[0044] The sterilization takes place by filtration at 0.2 microns and subsequent autoclave sterilization of the bags containing the solution at a T° C. 115-118° C. F0>8. Sterilization eliminates all forms of life present in the solution and on the surface of the bag making the device sterile in its entirety. The sterility of the surface allows the product to be used in the operating theatre, minimizing the risk of microbial and viral contamination of the patient and the surrounding environment.

[0045] The whole production process from the preparation phase to the filling phase of the non-sterile bag must be effected under vacuum conditions and in the presence of nitrogen (oxygen content in the bulk<1 ppm).

[0046] Finally, a 100% visual inspection of the bags forming the lot is effected and packaging in labelled cardboard boxes.